Biotech · Private company
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Track this companyFree. Adds Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA to your Dealase workspace and tells you when its record changes.
Clinical trials223 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Background PAH TherapyPhase 3 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- SotaterceptPhase 3 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- ACE-083Phase 2 · Charcot-Marie-Tooth DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ACE-083Phase 2 · Facioscapulohumeral Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- DalanterceptPhase 2 · Squamous Cell Carcinoma of the Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- Dalantercept and axitinibPhase 2 · Advanced Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- Dalantercept plus sorafenibPhase 2 · Advanced Adult Hepatocellular CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- SOCPhase 2 · Pulmonary Arterial HypertensionClinicalTrials.gov · fetched Nov 12, 2026
- Sotatercept 0.3 mg/kgPhase 2 · Hypertension, PulmonaryClinicalTrials.gov · fetched Nov 12, 2026
- Sotatercept 0.3 mg/kg escalating to 0.7 mg/kgPhase 2 · Hypertension, PulmonaryClinicalTrials.gov · fetched Nov 12, 2026
- ACE-083Phase 1 · Musculoskeletal DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- MK-2225Phase 1 · Systemic Sclerosis With and Without Interstitial Lung DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials22
- Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.NOT_YET_RECRUITING · started Mar 15, 2026ClinicalTrials.gov NCT07487441 · fetched Nov 12, 2026
- A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)PHASE1 · TERMINATED · started Mar 10, 2023ClinicalTrials.gov NCT04948554 · fetched Nov 12, 2026
- Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)PHASE3 · TERMINATED · started Mar 18, 2022ClinicalTrials.gov NCT04811092 · fetched Nov 12, 2026
- A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)PHASE2 · COMPLETED · started Dec 29, 2021ClinicalTrials.gov NCT04945460 · fetched Nov 12, 2026
- A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)PHASE3 · COMPLETED · started Dec 1, 2021ClinicalTrials.gov NCT04896008 · fetched Nov 12, 2026
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)PHASE3 · COMPLETED · started Jan 25, 2021ClinicalTrials.gov NCT04576988 · fetched Nov 12, 2026
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaPHASE2 · RECRUITING · started Nov 7, 2019ClinicalTrials.gov NCT04143724 · fetched Nov 12, 2026
- Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)PHASE2 · TERMINATED · started May 10, 2019ClinicalTrials.gov NCT03943290 · fetched Nov 12, 2026
- A Study of Sotatercept for the Treatment of Pulmonary Arterial HypertensionPHASE2 · COMPLETED · started Apr 19, 2019ClinicalTrials.gov NCT03738150 · fetched Nov 12, 2026
- A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïvePHASE3 · ACTIVE_NOT_RECRUITING · started Jan 2, 2019ClinicalTrials.gov NCT03682536 · fetched Nov 12, 2026
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)PHASE2 · COMPLETED · started Jun 13, 2018ClinicalTrials.gov NCT03496207 · fetched Nov 12, 2026
- A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-ThalassemiaPHASE2 · COMPLETED · started Feb 5, 2018ClinicalTrials.gov NCT03342404 · fetched Nov 12, 2026
- Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseasePHASE2 · TERMINATED · started Jul 31, 2017ClinicalTrials.gov NCT03124459 · fetched Nov 12, 2026
- Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)PHASE2 · TERMINATED · started Nov 1, 2016ClinicalTrials.gov NCT02927080 · fetched Nov 12, 2026
- An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) ThalassemiaPHASE3 · COMPLETED · started May 2, 2016ClinicalTrials.gov NCT02604433 · fetched Nov 12, 2026
- A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesPHASE3 · COMPLETED · started Feb 9, 2016ClinicalTrials.gov NCT02631070 · fetched Nov 12, 2026
- Phase 1 Study of ACE-083 in Healthy SubjectsPHASE1 · COMPLETED · started Sep 1, 2014ClinicalTrials.gov NCT02257489 · fetched Nov 12, 2026
- Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular CarcinomaPHASE1_PHASE2 · COMPLETED · started Aug 4, 2014ClinicalTrials.gov NCT02024087 · fetched Nov 12, 2026
- Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell CarcinomaPHASE2 · TERMINATED · started Dec 1, 2012ClinicalTrials.gov NCT01727336 · fetched Nov 12, 2026
- Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and NeckPHASE2 · COMPLETED · started Oct 1, 2011ClinicalTrials.gov NCT01458392 · fetched Nov 12, 2026
- A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.PHASE2 · COMPLETED · started Jun 30, 2010ClinicalTrials.gov NCT01146574 · fetched Nov 12, 2026
- A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal WomenPHASE1 · COMPLETED · started Jan 1, 2008ClinicalTrials.gov NCT00709540 · fetched Nov 12, 2026